Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 23 results for "tianjin medical university cancer ins..."

China moving to curb staggering rates of lung cancer
Sydney Morning Herald

China moving to curb staggering rates of lung cancer

The queues outside the Tianjin Medical University Cancer Institute and Hospital begin to form as early as 4am come much later, and you risk not getting face time with a doctor. China's public hospitals may ostensibly work on an appointment and ... Sydney Morning Herald, 1 month ago
[x]  

3 images for "tianjin medical university cancer institute and hospital"

The Land Australia, 1 month ago
Canberra Times, 1 month ago
Canberra Times, 1 month ago

Chinese Pharmaceutical Market: Forecasts and Outlooks 2014-2024

/PRNewswire/ -- Medical revenues in China - your guide to trends, companies and potentials What's the outlook for the Chinese pharma market ? Can it sustain high growth? Visiongain 's updated report gives you forecasted revenues there to 2024.
 Yahoo! Finance1 month ago

Protein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer - Abstract

Protein tyrosine kinase 7 (PTK7) has been studied in various tumors, but its role in prostate cancer remains unknown. This study is aimed to investigate the prognostic and predictive significance of PTK7 in patients with prostate cancer. PTK7 ...
 UroToday1 week ago
Medical News Today

Implanting 125I seeds into rat DRG for neuropathic pain: Only neuronal microdamage occurs

PUBLIC RELEASE DATE: 29-Jul-2014 The use of iodine-125 (125I) in cancer treatment has been shown to relieve patients' pain. Considering dorsal root ganglia are critical for neural transmission between the peripheral and central nervous systems, ...
 EurekAlert!1 month ago

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Results The median progression-free survival was 25.5 months with continuous lenalidomidedexamethasone, 20.7 months with 18 cycles of lenalidomidedexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for ...
 New England Journal of Medicine1 week ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less